We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

30 hedge funds and large institutions have $604K invested in Aspire Biopharma Warrant in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 33 → 30 (-3)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

86% less capital invested

Capital invested by funds: $4.47M → $604K (-$3.87M)

Holders
30
Holders Change
-3
Holders Change %
-9.09%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
2
Closed
6
Calls
$798K
Puts
–
Net Calls
+$798K
Net Calls Change
+$74K

Top Buyers

Rank Fund Capital Flow
1
CCM
Context Capital Management
California
+$8.33K
2
CS
Clear Street
New York
+$4.07K
3
BOCH
Blue Owl Capital Holdings
New York
+$2.38K
4
CAC
Cowen and Company
New York
+$1.37K
5
HF
HRT Financial
New York
+$675

Top Sellers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
-$12.5K
2
LP
LMR Partners
United Kingdom
-$5.95K
3
FSI
Flow State Investments
Illinois
-$5.1K
4
KL
KIM LLC
Kansas
-$4.49K
5
EAM
Exos Asset Management
New York
-$4.11K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Athos Capital
Hong Kong
$261K – – –
HCM
2
Highbridge Capital Management
New York
$72K – – –
SCM
3
Saba Capital Management
New York
$41.6K – – –
LA
4
Linden Advisors
New York
$34K – – –
AA
5
AQR Arbitrage
Connecticut
$27.4K – – –
PC
6
Periscope Capital
Ontario, Canada
$23.5K -$12.5K -262,300 -32%
SC
7
Sculptor Capital
New York
$18.9K – – –
Verition Fund Management
8
Verition Fund Management
Connecticut
$18.3K – – –
WAM
9
Wolverine Asset Management
Illinois
$17K – – –
Barclays
10
Barclays
United Kingdom
$14.8K – – –
TCA
11
Taconic Capital Advisors
New York
$12.7K – – –
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$8.46K – – –
CCM
13
Context Capital Management
California
$7.4K +$8.33K +175,000 New
Nomura Holdings
14
Nomura Holdings
Japan
$6.3K – – –
CS
15
Clear Street
New York
$5.86K +$4.07K +85,567 +161%
PAMP
16
Polar Asset Management Partners
Ontario, Canada
$5.86K – – –
WA
17
Whitebox Advisors
Minnesota
$5.29K – – –
CSD
18
Clear Street Derivatives
New York
$4.48K – – –
JP Morgan Chase
19
JP Morgan Chase
New York
$4.23K – – –
CCM
20
CAAS Capital Management
New York
$3.17K – – –
BOCH
21
Blue Owl Capital Holdings
New York
$2K +$2.38K +50,000 New
Walleye Capital
22
Walleye Capital
New York
$1.97K – – –
CAC
23
Cowen and Company
New York
$1.21K +$1.37K +28,700 New
Walleye Trading
24
Walleye Trading
New York
$1.11K – – –
OAC
25
OMERS Administration Corp
Ontario, Canada
$1.06K – – –
1
2

ASBPW Hedge Fund Activity: Q3 2024 in Review

30 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q3 2024, worth a combined $604K — down 86% from $4.47M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ASBPW and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Context Capital Management, opening a new position worth an estimated $8.33K. The largest seller was Periscope Capital, cutting an estimated $12.5K.

  • 30 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q3 2024, down from 33 in Q2 2024.
  • Funds reported $604K of Aspire Biopharma Warrant stock for Q3 2024, down 86% quarter-over-quarter.
  • 4 funds opened new Aspire Biopharma Warrant positions in Q3 2024 and 6 closed out, a net change of -2 holders.
  • The largest Aspire Biopharma Warrant buyer in Q3 2024 was Context Capital Management, an estimated $8.33K added.
  • The largest Aspire Biopharma Warrant seller in Q3 2024 was Periscope Capital, an estimated $12.5K sold.

Based on aggregated 13F filings for Q3 2024.